B-cell Hodgkin's Lymphoma

Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma

1. Patients with refractory diffuse large B-cell or follicular lymphoma demonstrated high rates of remission when treated with anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy. 2. Serious adverse events noticed in this cohort included cytokine release syndrome and encephalopathy. Evidence Rating Level: 3 (Average) Study Rundown: Diffuse large B-cell lymphoma and follicular lymphoma comprise []

Pretreating aggressive lymphoma with targeted therapy improves chemo effectiveness


Patients with diffuse large B-cell lymphoma, which often relapses and kills within 2 years, experienced a remission of their cancer and stayed disease-free as long as 28 months after taking a commercially available drug that made chemotherapy more effective.

Differentiating type is key to non-Hodgkin lymphomas

Differentiating type is key to non-Hodgkin lymphomas


Management and prognosis for patients with NHL depend on identifying the disease type. This review discusses the diagnoses and optimal treatments.

Smoking and Hodgkin's lymphoma

Smoking appears to increase the risk of Hodgkin's lymphoma, a prospective study has shown.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs